# The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: a systematic review and meta-analysis

**Authors:** Zechen Zhang, Yuyi Li, Jinkun Li, Yifeng Yuan, Kang Liu, Xiaolin Shi

PMC · DOI: 10.3389/fendo.2025.1703116 · Frontiers in Endocrinology · 2025-11-05

## TL;DR

This study finds that vitamin K2 improves bone metabolism markers in postmenopausal osteoporosis patients, suggesting potential benefits for bone health.

## Contribution

A systematic review and meta-analysis showing vitamin K2's impact on specific bone turnover markers in postmenopausal osteoporosis patients.

## Key findings

- Vitamin K2 increased osteocalcin and bone-specific alkaline phosphatase levels.
- Vitamin K2 reduced undercarboxylated osteocalcin and tartrate-resistant acid phosphatase.
- C-terminal telopeptide decreased slightly, but clinical relevance is uncertain.

## Abstract

Osteoporosis is a metabolic bone disease characterized by decreased bone mass and increased fracture risk. Bone turnover markers, such as osteocalcin (OC), undercarboxylated osteocalcin (ucOC), and other biochemical indicators, are important for assessing bone metabolism. Vitamin K2 influences bone metabolism by enhancing osteocalcin γ-carboxylation.

This study followed PRISMA guidelines and included randomized controlled trials on the effects of vitamin K2 supplementation on bone turnover biomarkers in postmenopausal osteoporosis patients. Key outcomes included changes in OC, ucOC, and other bone metabolism markers.

Nine studies with 2,570 participants were included. Vitamin K2 (VK2) increased osteocalcin (OC; MD 1.86, 95% CI 1.17–2.56) and bone-specific alkaline phosphatase (BAP; MD 1.49, 95% CI 0.98–2.00). It reduced undercarboxylated OC (ucOC; WMD −1.54, 95% CI −2.44 to −0.64) and tartrate-resistant acid phosphatase (TRAP; MD −0.83, 95% CI −1.21 to −0.46). C-terminal telopeptide (CTX) showed a small, statistically significant reduction (MD −0.09, 95% CI −0.14 to −0.05) with uncertain clinical relevance. N-telopeptide (NTX) showed no significant change.

Vitamin K2 supplementation improves key bone turnover biomarkers, particularly OC and ucOC. These findings support its role in bone metabolism, though further long-term studies are needed to confirm clinical benefits, such as increased bone mineral density.

https://www.crd.york.ac.uk/PROSPERO/view/CRD420251087067, identifier CRD420251087067.

## Linked entities

- **Proteins:** bglap2 (bone gamma-carboxyglutamate (gla) protein (osteocalcin) 2)
- **Chemicals:** vitamin K2 (PubChem CID 4056)
- **Diseases:** osteoporosis (MONDO:0005298)

## Full-text entities

- **Genes:** BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}, TRAP [NCBI Gene 100187907], PHB2 (prohibitin 2) [NCBI Gene 11331] {aka BAP, BCAP37, Bap37, PNAS-141, REA, hBAP}
- **Diseases:** Osteoporosis (MESH:D010024), bone disease (MESH:D001847), fracture (MESH:D050723)
- **Chemicals:** VK2 (MESH:D024482), CTX (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12626859/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12626859/full.md

## References

45 references — full list in the complete paper: https://tomesphere.com/paper/PMC12626859/full.md

---
Source: https://tomesphere.com/paper/PMC12626859